Lysosome Targeted Nanoparticle Aggregation Reverses Immunosuppressive Tumor Microenvironment for Cancer Immunotherapy

被引:2
|
作者
Xing, Yumeng [1 ,2 ,3 ]
Yang, Jianhui [1 ,2 ]
Peng, Ao [1 ,2 ]
Qian, Yujing [1 ,2 ]
Liu, Yang [4 ]
Pan, Pei [2 ]
Liu, Qi [1 ,2 ]
机构
[1] Anhui Med Univ, Affiliated Hosp 2, Res Ctr Translat Med, Hefei 230032, Peoples R China
[2] Anhui Med Univ, Sch Pharm, Hefei 230032, Peoples R China
[3] Xiamen Univ, Coll Chem & Chem Engn, Xiamen 361005, Peoples R China
[4] Nankai Univ, Coll Chem, Tianjin 300071, Peoples R China
基金
中国国家自然科学基金;
关键词
cancer immunotherapy; immunogenic cell death; lysosomal membrane permeabilization; nanoparticle aggregation; PD-1/PD-L1; blockade; MEMBRANE PERMEABILIZATION; CELL-DEATH;
D O I
10.1002/adma.202412730
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Nanotechnology has proven its enormous application value in clinical practice. However, current research on nanomedicines mainly focuses on developing nanoparticles as delivery carriers to maximize the bioavailability of therapeutic agents, with little attention on exploring their potential to directly regulate physiological processes. In this study, inspired by the lysosomal swelling caused by excessive accumulation of undegraded substances, this work presents a lysosomal-targeting aggregated nanoparticle (LTANP) for cancer treatment. By rationally engineering surface composition, properties, and interparticle interactions, LTANP achieves efficient tumor accumulation and selective targeted aggregation in lysosomes of cancer cells, leading to unrelievable lysosomal swelling, and ultimately inducing lysosomal membrane permeabilization (LMP) of cancer cells. Further analysis shows that nanoparticle aggregation-mediated LMP can effectively trigger immunogenic cell death (ICD) by impairing autophagy-lysosome pathway, evoking robust antitumor immune responses and reversing tumor immunogenicity from "cold" to "hot" in a melanoma model. Additionally, LTANP can combine with clinically approved programmed death ligand-1 (PD-L1) antibodies to further unleash T cell-mediated antitumor immunity, significantly enhancing antitumor performance, inhibiting tumor recurrence and metastasis. This work demonstrates the potential of rationally engineered nanostructures in directly combating cancer and provides novel insights for the development of advanced nanoparticle-based cancer treatment. Inspired by the lysosomal swelling caused by excessive accumulation of undegraded substances, a lysosomal-targeting aggregated nanoparticle (LTANP) is synthesized for cancer treatment. By rationally engineering surface properties and interparticle interactions, LTANP enables targeted aggregation in lysosomes of cancer cells, leading to unrelievable lysosomal swelling, and ultimately selectively inducing lysosomal membrane permeabilization and immunogenic cell death of cancer cells. image
引用
收藏
页数:17
相关论文
共 50 条
  • [41] The Role of Tumor Microenvironment in Cancer Immunotherapy
    Frankel, Timothy
    Lanfranca, Mirna Perusina
    Zou, Weiping
    TUMOR IMMUNE MICROENVIRONMENT IN CANCER PROGRESSION AND CANCER THERAPY, 2017, 1036 : 51 - 64
  • [42] The Role of Tumor Microenvironment in Cancer Immunotherapy
    Chen Xue-Man
    Song Er-Wei
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2017, 44 (08) : 641 - 648
  • [43] Tumor microenvironment and immunotherapy of oral cancer
    Liu, Chang
    Wang, Min
    Zhang, Haiyang
    Li, Chunyan
    Zhang, Tianshou
    Liu, Hong
    Zhu, Song
    Chen, Jie
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2022, 27 (01)
  • [44] Reprogramming tumor microenvironment in cancer immunotherapy
    Kalinski, Pawel
    Muthuswamy, Ravikumar
    Obermajer, Natasa
    Zeh, Herbert
    Zureikat, Amer
    Edwards, Robert
    Bartlett, David
    JOURNAL OF IMMUNOLOGY, 2013, 190
  • [45] Toward a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment
    Gomes-da-Silva, Ligia C.
    Santos, Adriana O.
    Bimbo, Luis M.
    Moura, Vera
    Ramalho, Jose S.
    Pedroso de Lima, Maria C.
    Simoes, Sergio
    Moreira, Joao N.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2012, 434 (1-2) : 9 - 19
  • [46] Nanoparticle-Mediated Targeted Drug Delivery to Remodel Tumor Microenvironment for Cancer Therapy
    Tang, Lu
    Mei, Yijun
    Shen, Yan
    He, Shun
    Xiao, Qiaqia
    Yin, Yue
    Xu, Yonggang
    Shao, Jie
    Wang, Wei
    Cai, Zihao
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2021, 16 : 5811 - 5829
  • [47] RNA NANOPARTICLE VACCINES OVERCOME THE IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT OF METASTATIC OSTEOSARCOMA
    Ligon, John
    Stover, Brian
    Mendez-Gomez, Hector
    Grippin, Adam
    Weidert, Frances
    Fagman, Lana
    Chardon-Robles, Jonathan
    Castillo, Paul
    Silver, Natalie
    Lagmay, Joanne
    Milner, Rowan
    Mitchell, Duane
    Sayour, Elias
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1444 - A1444
  • [48] Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives
    Shen, Ke-Yu
    Zhu, Ying
    Xie, Sun-Zhe
    Qin, Lun-Xiu
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01) : 25
  • [49] Reprogramming the immunosuppressive tumor microenvironment: exploiting angiogenesis and thrombosis to enhance immunotherapy
    Shafqat, Areez
    Omer, Mohamed H.
    Ahmed, Eman Nayaz
    Mushtaq, Ali
    Ijaz, Eman
    Ahmed, Zara
    Alkattan, Khaled
    Yaqinuddin, Ahmed
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [50] Enhancing photodynamic immunotherapy by reprograming the immunosuppressive tumor microenvironment with hypoxia relief
    He, Mengying
    Zhang, Mengyao
    Xu, Tao
    Xue, Shujuan
    Li, Dazhao
    Zhao, Yanan
    Zhi, Feng
    Ding, Dawei
    JOURNAL OF CONTROLLED RELEASE, 2024, 368 : 233 - 250